Table 1.
Baseline Patient Characteristics
| Characteristic | Treatment Arm |
|||
|---|---|---|---|---|
| TMZ/BCNU (n = 56) |
Erlotinib (n = 54) |
|||
| No. | % | No. | % | |
| Age, years | ||||
| Median | 54.2 | 54.7 | ||
| Range | 19.5-78.8 | 18.7-71.4 | ||
| Sex | ||||
| Male | 37 | 66.1 | 35 | 64.8 |
| Female | 19 | 33.9 | 19 | 35.2 |
| Karnofsky performance status | ||||
| 70-80 | 26 | 46.4 | 24 | 44.4 |
| 90-100 | 30 | 53.6 | 30 | 55.6 |
| Prior adjuvant chemotherapy | ||||
| No | 20 | 35.7 | 19 | 35.2 |
| Yes | 36 | 64.3 | 35 | 64.8 |
| Antiepileptic treatment | ||||
| No | 23 | 41.1 | 18 | 33.3 |
| EIAED | 14 | 25.0 | 9 | 16.7 |
| Non-EIAED | 19 | 33.9 | 27 | 50.0 |
Abbreviations: TMZ, temozolomide; BCNU, carmustine; EIAED, enzyme-inducing anticonvulsant.